TIDMAGL
RNS Number : 2829O
Angle PLC
04 November 2016
For immediate release 4 November 2016
ANGLE plc
("ANGLE" or "the Company")
ANGLE WELCOMES NEW RESEARCH FROM BARTS SUPPORTING POTENTIAL USE
OF PARSORTIX TO DETECT AND MONITOR PROSTATE CANCER
Simple blood test could become effective diagnostic
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, welcomes new research presented during the National Cancer
Research Institute (NCRI) annual conference, 6-9 November 2016,
which supports the potential use of the Company's Parsortix cell
separation technology. This research details the use of Parsortix
as part of a simple blood test, to diagnose and monitor patients
with prostate cancer.
Using Parsortix, scientists at the Barts Cancer Institute at
Queen Mary University were able to capture a very specific subset
of circulating tumour cells (CTCs) from prostate cancer patient
blood samples. These CTCs, which cannot be captured by traditional
systems, are linked to the spread of the disease and as such could
potentially be used, in future, to stage the severity of the
prostate cancer and thereafter as a means of monitoring the
patient.
Commenting on the research ANGLE's Founder and Chief Executive,
Andrew Newland, said
"This is a significant milestone, which further supports the
adoption of Parsortix as a non-invasive alternative to the biopsy
of prostate tissue. Biopsy is the current standard of care for men
suspected of prostate cancer and yet 75% to 80% of men enduring a
biopsy and running the risk of potentially serious complications,
do not have prostate cancer. Less than 10% of biopsied patients
have aggressive cancer where treatment is recommended. Aside from
being non-invasive, Parsortix has the potential to provide the
additional staging information to allow physicians to determine
which patients require treatment and to provide active monitoring
for all prostate cancer patients. We look forward to our continued
work with Barts to progress the use of Parsortix in prostate
cancer."
The full text of the announcement from The National Cancer
Research Institute (NCRI) is as follows:
TUMOUR CELLS IN BLOOD SAMPLES COULD PREDICT
PROSTATE CANCER SPREAD
RESEARCHERS have found a group of circulating tumour cells in
prostate cancer patient blood samples which are linked to the
spread of the disease, according to new research* presented at the
National Cancer Research Institute (NCRI) Cancer Conference in
Liverpool.
This is the first time these cell types have been shown to be a
promising marker for prostate cancer spread.
In a study of around 80 samples from men with prostate cancer,
scientists at the Barts Cancer Institute at Queen Mary University
looked for cells that were gaining the ability to migrate and
invade through the body.**
Samples with more of these cells were more likely to come from
patients whose cancer had spread or was more aggressive.
This means that, in the future, these particular cells could
potentially be used as a marker to monitor prostate cancer patients
and predict if the disease is going to spread - alongside other
monitoring techniques.
There are around 46,500 new cases of prostate cancer each year
in the UK, and around 11,000 people die from the disease each
year.
Dr Yong-Jie Lu, lead author from QMUL's Barts Cancer Institute,
said:
"Our research shows that the number of these specific cells in a
patient's sample is a good indicator of prostate cancer spreading.
By identifying these cells, which have gained the ability to move
through the body, we have found a potential new way to monitor the
disease.
"If we're able to replicate these studies in larger groups of
people, we may be able to one day predict the risk of someone's
cancer spreading so they can make more informed treatment
decisions."
Dr Chris Parker, Chair of the NCRI's Prostate Cancer Clinical
Studies Group, said:
"There's a need to develop better tests to identify and monitor
men with aggressive prostate cancer. This research has found a
promising new marker that could one day make it to the clinic to
guide treatment decisions."
This research was funded by Orchid Cancer Appeal, ANGLE plc and
Chinese Scholarship Council. The scientists used a highly
innovative cell separation technology Parsortix(TM), developed by
UK company ANGLE plc that is able to capture the circulating tumour
cells.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser)
Russell Kerr, Oliver Baxendale
(Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes to editor:
* Abstract: Capture of circulating tumour cells with epithelial
and mesenchymal features for prostate cancer prognosis
** This is known as epithelial to mesenchymal transition
(EMT).
About the NCRI
The National Cancer Research Institute (NCRI) is a UK-wide
partnership of cancer research funders, established in 2001. Its 19
member organisations work together to accelerate progress in
cancer-related research through collaboration, to improve health
and quality of life.
NCRI works to coordinate research related to cancer, to improve
the quality and relevance of the research and to accelerate
translation of the research into clinical practice for the benefit
of patients.
NCRI members are: Biotechnology and Biological Sciences Research
Council; Bloodwise; Breast Cancer Now; Cancer Research UK; Children
with Cancer UK, Department of Health; Economic and Social Research
Council (ESRC); Macmillan Cancer Support; Marie Curie; Medical
Research Council (MRC); Northern Ireland Health and Social Care
Public Health Agency (Research & Development Department);
Pancreatic Cancer Research Fund; Prostate Cancer UK; Roy Castle
Lung Cancer Foundation; Scottish Government Health Directorates
(Chief Scientist Office); Tenovus Cancer Care; The Wellcome Trust;
Welsh Assembly Government (Health and Care Research Wales); and
Worldwide Cancer Research.
For more information visit www.ncri.org.uk
About the NCRI Cancer Conference
The NCRI Cancer Conference is the UK's largest cancer research
forum for showcasing the latest advances in British and
international oncological research spanning basic and translational
studies to clinical trials and patient involvement.
-- The conference offers unique opportunities to network and
share knowledge by bringing together world-leading experts from all
cancer research disciplines.
-- The NCRI Cancer Conference is taking place from 6-9 November
2016 at the BT Convention Centre in Liverpool.
-- For more information visit conference.ncri.org.uk; Twitter @NCRI_Partners; #NCRI2016
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China and
Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEALFDEAXKFFF
(END) Dow Jones Newswires
November 04, 2016 03:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
